Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A population-based approach to compare patient-reported outcomes of long-term Hodgkin's lymphoma survivors according to trial participation: a joint study from the Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship registry and European Organisation for Research and Treatment of Cancer.
Thong MSY, Kicinski M, Coens C, Giusti F, van de Poll-Franse L, Bogaerts J, Liu L. Thong MSY, et al. Among authors: giusti f. Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S223-S228. doi: 10.1097/CEJ.0000000000000381. Eur J Cancer Prev. 2017. PMID: 28574866
Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.
Liu L, Giusti F, Schaapveld M, Aleman B, Lugtenburg P, Meijnders P, Hutchings M, Lemmens V, Bogaerts J, Visser O. Liu L, et al. Among authors: giusti f. Br J Haematol. 2017 Jan;176(1):65-75. doi: 10.1111/bjh.14379. Epub 2016 Oct 21. Br J Haematol. 2017. PMID: 27766636 Free article.
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials.
Maraldo MV, Giusti F, Vogelius IR, Lundemann M, van der Kaaij MA, Ramadan S, Meulemans B, Henry-Amar M, Aleman BM, Raemaekers J, Meijnders P, Moser EC, Kluin-Nelemans HC, Feugier P, Casasnovas O, Fortpied C, Specht L; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group. Maraldo MV, et al. Among authors: giusti f. Lancet Haematol. 2015 Nov;2(11):e492-502. doi: 10.1016/S2352-3026(15)00153-2. Epub 2015 Oct 22. Lancet Haematol. 2015. PMID: 26686259
Cancer registries - guardians of breast cancer biomarker information: A systematic review.
Voith von Voithenberg L, Crocetti E, Martos C, Dimitrova N, Giusti F, Randi G, Rooney R, Dyba T, Bettio M, Negrão Carvalho R. Voith von Voithenberg L, et al. Among authors: giusti f. Int J Biol Markers. 2019 Jun;34(2):194-199. doi: 10.1177/1724600819836097. Epub 2019 Apr 10. Int J Biol Markers. 2019. PMID: 30968746 Free article.
Cancer cure for 32 cancer types: results from the EUROCARE-5 study.
Dal Maso L, Panato C, Tavilla A, Guzzinati S, Serraino D, Mallone S, Botta L, Boussari O, Capocaccia R, Colonna M, Crocetti E, Dumas A, Dyba T, Franceschi S, Gatta G, Gigli A, Giusti F, Jooste V, Minicozzi P, Neamtiu L, Romain G, Zorzi M, De Angelis R, Francisci S; EUROCARE-5 Working Group. Dal Maso L, et al. Among authors: giusti f. Int J Epidemiol. 2020 Oct 1;49(5):1517-1525. doi: 10.1093/ije/dyaa128. Int J Epidemiol. 2020. PMID: 32984907
337 results